Chronic obstructive pulmonary disease exacerbation resident survival guide: Difference between revisions
Gerald Chi (talk | contribs) m (→Assessment) |
Gerald Chi (talk | contribs) m (→Do's) |
||
Line 81: | Line 81: | ||
* The presence of purulent sputum during an exacerbation can be sufficient indication for starting empirical antibiotic treatment.<ref name="Stockley-2000">{{Cite journal | last1 = Stockley | first1 = RA. | last2 = O'Brien | first2 = C. | last3 = Pye | first3 = A. | last4 = Hill | first4 = SL. | title = Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. | journal = Chest | volume = 117 | issue = 6 | pages = 1638-45 | month = Jun | year = 2000 | doi = | PMID = 10858396 }}</ref> | * The presence of purulent sputum during an exacerbation can be sufficient indication for starting empirical antibiotic treatment.<ref name="Stockley-2000">{{Cite journal | last1 = Stockley | first1 = RA. | last2 = O'Brien | first2 = C. | last3 = Pye | first3 = A. | last4 = Hill | first4 = SL. | title = Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. | journal = Chest | volume = 117 | issue = 6 | pages = 1638-45 | month = Jun | year = 2000 | doi = | PMID = 10858396 }}</ref> | ||
===Bronchodilators=== | |||
=====Antibiotics===== | |||
* [[Haemophilus influenzae]], [[Streptococcus pneumoniae]], and [[Moraxella catarrhalis]] are the most common bacterial pathogens involved in an exacerbation,<ref name="Sethi-2008">{{Cite journal | last1 = Sethi | first1 = S. | last2 = Murphy | first2 = TF. | title = Infection in the pathogenesis and course of chronic obstructive pulmonary disease. | journal = N Engl J Med | volume = 359 | issue = 22 | pages = 2355-65 | month = Nov | year = 2008 | doi = 10.1056/NEJMra0800353 | PMID = 19038881 }}</ref> However, the choice of the antibiotic should be based on the local bacterial resistance pattern. | |||
* Empirical coverage of [[Pseudomonas aeruginosa]] in GOLD 3 and GOLD 4 patients is important.<ref name="Vestbo-2013">{{Cite journal | last1 = Vestbo | first1 = J. | last2 = Hurd |first2 = SS. | last3 = Agustí |first3 = AG. | last4 = Jones | first4 = PW. | last5 = Vogelmeier | first5 = C. | last6 = Anzueto | first6 = A. | last7 = Barnes | first7 = PJ. | last8 = Fabbri | first8 = LM. | last9 = Martinez | first9 = FJ. | title = Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. | journal = Am J Respir Crit Care Med | volume = 187 | issue = 4 | pages = 347-65 | month = Feb | year = 2013 | doi = 10.1164/rccm.201204-0596PP | PMID = 22878278}}</ref> | |||
=====Bronchodilators===== | |||
* Short-acting inhaled β2-agonists with or without short-acting anticholinergics are usually the preferred bronchodilators for treatment of an exacerbation.<ref name="Celli-2004">{{Cite journal | last1 = Celli | first1 = BR. | last2 = MacNee | first2 = W. | title = Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. | journal = Eur Respir J | volume = 23 | issue = 6 | pages = 932-46 | month = Jun | year = 2004 | doi = | PMID = 15219010 }}</ref> | * Short-acting inhaled β2-agonists with or without short-acting anticholinergics are usually the preferred bronchodilators for treatment of an exacerbation.<ref name="Celli-2004">{{Cite journal | last1 = Celli | first1 = BR. | last2 = MacNee | first2 = W. | title = Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. | journal = Eur Respir J | volume = 23 | issue = 6 | pages = 932-46 | month = Jun | year = 2004 | doi = | PMID = 15219010 }}</ref> | ||
Revision as of 04:03, 15 December 2013
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Abdurahman Khalil, M.D. [2]
Definition
- Exacerbation of COPD is an acute event characterized by a worsening of the patient’s respiratory symptoms that is beyond normal day-to-day variations and leads to a change in medication.[1][2][3]
- The diagnosis of an exacerbation relies exclusively on the clinical presentation of the patient complaining of an acute change of symptoms (baseline dyspnea, cough, and/or sputum production) that is beyond normal day-to-day variation.[4]
Causes
Life-Threatening Causes
Life-threatening causes include conditions which may result in death or permanent disability within 24 hours if left untreated.
Common Causes
- Respiratory tract infections (~½)
- Unknown (~⅓)
- Air pollutants
Treatment Setting and Severity
COPD Exacerbation ❑ Cough ↑ ❑ Dyspnea ↑ ❑ Sputum ↑ | |||||||||||
1. Oxygen Supplement ❑ Pulse oximetry (maintain SaO2 ≥88—92%)[5] ❑ Arterial blood gas (if acute or acute-on-chronic respiratory failure is suspected) | |||||||||||
2. Indications for ICU Admission ❑ Hemodynamic instability ❑ Changes in mental status (confusion, lethargy, coma) ❑ Severe dyspnea that responds inadequately to initial emergency therapy ❑ Worsening hypoxemia (PaO2 <40 mm Hg) and/or respiratory acidosis (pH <7.25) | |||||||||||
2a. Indications for Noninvasive Mechanical Ventilation ❑ Respiratory acidosis (arterial pH < 7.35 or PaCO2 >45 mm Hg) ❑ Severe dyspnea with sings of respiratory muscle fatigue ❑ Increased work of breathing 2b. Indications for Invasive Mechanical Ventilation ❑ Diminished consciousness, psychomotor agitation inadequately controlled by sedation ❑ Severe hemodynamic instability without response to fluids and vasoactive drugs ❑ Respiratory pauses with loss of consciousness or gasping for air ❑ Life-threatening hypoxemia in patients unable to tolerate NIV ❑ Persistent inability to remove respiratory secretions ❑ Heart rate <50/min with loss of alertness ❑ Unable to tolerate NIV or NIV failure ❑ Severe ventricular arrhythmias ❑ Respiratory or cardiac arrest ❑ Massive aspiration | |||||||||||
3. Indications for Hospitalization 4. Assessment of Severity of Exacerbation ❑ Sputum purulence ❑ ECG (identify coexisting cardiac problems) ❑ Chest radiograph (exclude alternative diagnoses) ❑ Whole-blood count (identify polycythemia, anemia, or leukocytosis) ❑ Electrolytes and glucose (identify electrolyte disturbances or hyperglycemia) | |||||||||||
Severe Exacerbation Moderate Exacerbation Mild Exacerbation ❑ Consider outpatient management ❑ Require change of inhaled treatment by the patient | |||||||||||
Management
Do's
Assessment
- The presence of purulent sputum during an exacerbation can be sufficient indication for starting empirical antibiotic treatment.[6]
Antibiotics
- Haemophilus influenzae, Streptococcus pneumoniae, and Moraxella catarrhalis are the most common bacterial pathogens involved in an exacerbation,[7] However, the choice of the antibiotic should be based on the local bacterial resistance pattern.
- Empirical coverage of Pseudomonas aeruginosa in GOLD 3 and GOLD 4 patients is important.[4]
Bronchodilators
- Short-acting inhaled β2-agonists with or without short-acting anticholinergics are usually the preferred bronchodilators for treatment of an exacerbation.[8]
Don'ts
- Spirometry is not recommended during an exacerbation because it can be difficult to perform and measurements are not accurate enough.
References
- ↑ Burge, S.; Wedzicha, JA. (2003). "COPD exacerbations: definitions and classifications". Eur Respir J Suppl. 41: 46s–53s. PMID 12795331. Unknown parameter
|month=
ignored (help) - ↑ Celli, BR.; Barnes, PJ. (2007). "Exacerbations of chronic obstructive pulmonary disease". Eur Respir J. 29 (6): 1224–38. doi:10.1183/09031936.00109906. PMID 17540785. Unknown parameter
|month=
ignored (help) - ↑ Rodriguez-Roisin, R. (2000). "Toward a consensus definition for COPD exacerbations". Chest. 117 (5 Suppl 2): 398S–401S. PMID 10843984. Unknown parameter
|month=
ignored (help) - ↑ 4.0 4.1 Vestbo, J.; Hurd, SS.; Agustí, AG.; Jones, PW.; Vogelmeier, C.; Anzueto, A.; Barnes, PJ.; Fabbri, LM.; Martinez, FJ. (2013). "Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary". Am J Respir Crit Care Med. 187 (4): 347–65. doi:10.1164/rccm.201204-0596PP. PMID 22878278. Unknown parameter
|month=
ignored (help) - ↑ Austin, MA.; Wills, KE.; Blizzard, L.; Walters, EH.; Wood-Baker, R. (2010). "Effect of high flow oxygen on mortality in chronic obstructive pulmonary disease patients in prehospital setting: randomised controlled trial". BMJ. 341: c5462. PMID 20959284.
- ↑ Stockley, RA.; O'Brien, C.; Pye, A.; Hill, SL. (2000). "Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD". Chest. 117 (6): 1638–45. PMID 10858396. Unknown parameter
|month=
ignored (help) - ↑ Sethi, S.; Murphy, TF. (2008). "Infection in the pathogenesis and course of chronic obstructive pulmonary disease". N Engl J Med. 359 (22): 2355–65. doi:10.1056/NEJMra0800353. PMID 19038881. Unknown parameter
|month=
ignored (help) - ↑ Celli, BR.; MacNee, W. (2004). "Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper". Eur Respir J. 23 (6): 932–46. PMID 15219010. Unknown parameter
|month=
ignored (help)